SCHEMBL21394600

SCHEMBL21394600

Cn1nc(C(=O)Nc2ccc(Cc3cccc(Cl)c3)nn2)ccc1=O

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.47
TSHR P16473 1/20 0.45
HTT P42858 2/20 0.45
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
MAPT P10636 3/20 0.41
RAB9A P51151 3/20 0.41
NPC1 O15118 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
KDM4E B2RXH2 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
LMNA P02545 1/20 0.40
GRM5 P41594 1/20 0.40
GLS O94925 1/20 0.39
ALDH1A1 P00352 2/20 0.39
VNN1 O95497 1/20 0.39
ENPP2 Q13822 1/20 0.38
POLB P06746 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29356767 1.00 L3MBTL1 (0.47) L3MBTL1TSHRHTTMEN1KMT2A
SCHEMBL21394765 0.92 L3MBTL1 (0.42) L3MBTL1TSHRHTTMEN1KMT2A
SCHEMBL21394582 0.89 TSHR (0.47) L3MBTL1TSHRHTTMEN1KMT2A
SCHEMBL29358116 0.89 TSHR (0.47) L3MBTL1TSHRHTTMEN1KMT2A
SCHEMBL21394769 0.88 ALDH1A1 (0.40) MAPTRAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL29357829 0.88 ALDH1A1 (0.40) MAPTRAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL21394511 0.88 SMN1; SMN2 (0.41) L3MBTL1TSHRMAPTRAB9ANPC1
SCHEMBL29353756 0.88 SMN1; SMN2 (0.41) L3MBTL1TSHRMAPTRAB9ANPC1
SCHEMBL22479444 0.86 L3MBTL1 (0.46) L3MBTL1TSHRHTTMEN1KMT2A
SCHEMBL21394434 0.86 L3MBTL1 (0.46) L3MBTL1TSHRHTTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12180221-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-12-31 US disclosed
CN-118084800-A Compounds and uses thereof 詹森药业有限公司 2024-05-28 CN disclosed
CN-118084801-A Compounds and uses thereof 詹森药业有限公司 2024-05-28 CN disclosed
CN-112312913-B Compounds and uses thereof 詹森药业有限公司 2024-03-08 CN disclosed
US-20230078764-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2023-03-16 US disclosed
US-20220298168-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2022-09-22 US disclosed
CN-114174273-A Compounds and uses thereof 优曼尼蒂治疗公司 2022-03-11 CN disclosed
CN-112312913-A Compounds and uses thereof 优曼尼蒂治疗公司 2021-02-02 CN disclosed
WO-2020198026-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS, INC. (US) 2020-10-01 WO disclosed
WO-2019183587-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS, INC. (US) 2019-09-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230078764-A1 COMPOUNDS AND USES THEREOF NLN, BDNF, NQO1 L3MBTL1 3090/4885TSHR 4560/4885HTT 216/4885
US-20220298168-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 L3MBTL1 3366/4885TSHR 4679/4885HTT 6/4885
US-12180221-B2 Compounds and uses thereof NLN, ACHE, CLN6 L3MBTL1 3366/4885TSHR 4679/4885HTT 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.